Research > Clinical Trial Listings > Active Trial Listings - Herman & Walter Samuelson Children's Hospital

Active Trial Listings - Herman & Walter Samuelson Children's Hospital


Acute Leukemia

COG ACCL0934: A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplant (HSCT).
PI: Jason M. Fixler, M.D.  *Accrual Closure*

Acute Lymphoblastic Leukemia

COG AALL1122 (BMS CA180-372): A Phase 2 Multi-Center Historically-Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. *Accrual Closure*
PI: Jason M. Fixler, M.D.

COG AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSVC# 606869) in the Very High Risk Stratum: A Groupwide Phase III Study.
PI: Jason M. Fixler, M.D.

COG AALL0932: Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL).
PI: Jason M. Fixler, M.D.

Acute Myeloid Leukemia

COG AAML1031: A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC#681239) and Sorafenib (BAY 43-9006, IND# 69896. MSC# 724772) for Patients with High Allelic Ratio FLT#/ITD: A Groupwide Phase II/III Study.
PI: Jason M. Fixler, M.D.

Acute Promyelocytic Leukemia

COG AAML1331: A Phase III Study for Patients with newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid: A COG Groupwide Phase III Study
PI: Jason M. Fixler, M.D.

Anaplastic Large Cell Lymphomas

COG ANHL12P1: A Randomized Phase II Trial of Brentuximab Vedotion or Crizotinib in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL).
PI: Jason M. Fixler, M.D.

Desmoplastic Medulloblastoma

COG ACNS1221: A Phase II Study for the Treatment of Non-Metastatic Nodular Desmoplatic Medulloblastoma in Children Less Than 4 Years of Age
PI: Jason M. Fixler, M.D. *Accrual Closure*

Ewing Sarcoma

COG AEWS1031: A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma.
PI: Jason M. Fixler, M.D. *Accrual Closure*

COG AEWS1221: Randomized Phase II Trail Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 470, NSC# 75008, IND# 120449) to Multiagent
Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma: An Intergroup NCTN Phase II Study.

PI: Jason M. Fixler, M.D. *Accrual Closure*

Fungal Infection

COG ACCL0933: A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML).
PI: Jason M. Fixler, M.D. *Accrual Closure*

Lymphoma/Leukemia

COG AALL1231: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-All) and T-Lymphoblastic Lymphoma (T-LLy)
PI: Jason M. Fixler, M.D.

Hepatoblastoma

COG AHEP0731: Treatment of Children with All Stages of Hepatoblastoma.
PI: Jason M. Fixler, M.D.

Hodgkin's Disease

COG AHOD1221: A Phase 1/2 Trial of Brentuximab Vedotin (SGN35, IND# 117117) in Combination with Gemcitabine for Pediatric and Young Adult Patients with Relapsed or Refractory Hodgkin Lymphoma
PI: Jason M. Fixler, M.D.

Hodgkin's Lymphoma

COG AHOD1331: A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND# 117117) for Newly Diagnosed High-Risk classical Hodgkin Lymphoma (cHL) in Children and Adolescents: A Groupwide Phase III Study
PI: Jason M. Fixler, M.D. 

Neuroblastoma

COG ANBL1221: A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC#683864, INC#61010) or Chimeric 14.18 Antibody (ch14.18(NSC#623408, IND# 4308) in Children with Refractory, Relapased or Progressive Neuroblastoma.
PI: Jason M. Fixler, M.D.

COG ANBL1232: Utilizing Response-and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma.
PI: Jason M. Fixler, M.D.

Non-Hodgkin’s Lymphoma

COG ANHL1131: Intergroup Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma (NHL) or Mature B-cell Leukemia (B-AL): Evaluation of Rituximab Efficacy and Safety in High Risk Patients. *Accrual Closure*
PI: Jason M. Fixler, M.D.

Non-Rhabdomyosarcoma Soft Tissure Sarcomas

COG ARST1321: Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus
Pazopanib (NSC# 737754, IND# 118613)

PI: Jason M. Fixler, M.D.

Osteosarcoma

COG AOST1322: Phase II Study of Eribulin (NSC#707389, IND#122686) in Recurrent or Refractory Osteosarcoma.
PI: Jason M. Fixler, M.D.

COG AOST1321: Phase II Study of Denosumab (IND#127430, NSC#744010), a Rank Ligand Antibody, for Recurrent of Refractory Osteosarcoma.
PI: Jason M. Fixler, M.D.

Sickle Cell Anemia

Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-Up Observational Study II. *Accrual Closure*
PI: Jason M. Fixler, M.D. 

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of MST-188 (Purified Poloxamer 188) Injection in Children with Sickle Cell Disease Experiencing Vaso-Occlusive Crisis (MST-188-01).
PI: Jason M. Fixler, M.D.

Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children (HU Prevent).
PI: Jason M. Fixler, M.D.

Wilms Tumor

**CLOSED** COG AREN0534: Treatment for Patients with Bilateral, Multicentric, or Bilaterally Predisposed Unilateral Wilms Tumor.